<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25706652</article-id><article-id pub-id-type="pmc">4338154</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0116299</article-id><article-id pub-id-type="publisher-id">PONE-D-14-05807</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Kericho CLinic-Based ART Diagnostic Evaluation (CLADE): Design, Accrual, and Baseline Characteristics of a Randomized Controlled Trial Conducted in Predominately Rural, District-Level, HIV Clinics of Kenya</article-title><alt-title alt-title-type="running-head">CLADE Baseline Methods</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sawe</surname><given-names>Fredrick K.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Obiero</surname><given-names>Eunice</given-names></name><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yegon</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Langat</surname><given-names>Rither C.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Aoko</surname><given-names>Appolonia</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tarus</surname><given-names>Jemutai</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kiptoo</surname><given-names>Ignatius</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Langat</surname><given-names>Raphael K.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Maswai</surname><given-names>Jonah</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bii</surname><given-names>Margaret</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Khamadi</surname><given-names>Samoel</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Shikuku</surname><given-names>Kibet P.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Close</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sinei</surname><given-names>Samuel</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Shaffer</surname><given-names>Douglas N.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref><xref ref-type="author-notes" rid="currentaff001">
<sup>&#x000a4;</sup>
</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Kenya Medical Research Institute/Walter Reed Project, Kericho, Kenya</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States of America</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, United States of America</addr-line>
</aff><aff id="aff004">
<label>4</label>
<addr-line>Kericho District Hospital, Kenya Ministry of Public Health and Sanitation, Kericho, Kenya</addr-line>
</aff><aff id="aff005">
<label>5</label>
<addr-line>HJF Medical Research International, Inc., Kericho, Kenya</addr-line>
</aff><aff id="aff006">
<label>6</label>
<addr-line>EmpiriStat, Mt Airy, MD, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Law</surname><given-names>Matthew</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of New South Wales, AUSTRALIA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The team commits to following PLOS ONE policy and assures PLOS ONE the authors have no competing interests. Empiristat is often contracted by the United States Military HIV Research Program for technical data support. For CLADE, Dr. Close (of Empiristat) provided analytical support and validation of analyses as part of capacity development to Mr. Yegon (as outlined in the original submitted manuscript, page 12, paragraph 3). This does not alter the authors&#x02019; adherence to PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: FKS EO PY RCL AA JT IK RKL JM MB SK KPS NC SS DNS. Performed the experiments: FKS EO PY RCL AA JT IK RKL JM MB SK KPS NC SS DNS. Analyzed the data: FKS EO PY RCL AA JT IK RKL JM MB SK KPS NC SS DNS. Contributed reagents/materials/analysis tools: FKS DNS PY RKL NC KPS RCL. Wrote the paper: FKS DNS PY.</p></fn><fn fn-type="current-aff" id="currentaff001"><label>&#x000a4;</label><p>Current address: Centers for Disease Control and Prevention, Kigali, Rwanda</p></fn><corresp id="cor001">* E-mail: <email>Fredrick.Sawe@usamru-k.org</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>2</issue><elocation-id>e0116299</elocation-id><history><date date-type="received"><day>24</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>2</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Sawe et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Sawe et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0116299.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Prospective clinical trial data regarding routine HIV-1 viral load (VL) monitoring of antiretroviral therapy (ART) in non-research clinics of Sub-Saharan Africa are needed for policy makers.</p></sec><sec id="sec002"><title>Methods</title><p>
<underline>CL</underline>inic-based <underline>A</underline>RT <underline>D</underline>iagnostic <underline>E</underline>valuation (CLADE) is a randomized, controlled trial (RCT) evaluating feasibility, superiority, and cost-effectiveness of routine VL vs. standard of care (clinical and immunological) monitoring in adults initiating dual nucleoside reverse transcriptase inhibitor (NRTI)+non-NRTI ART. Participants were randomized (1:1) at 7 predominately rural, non-research, district-level clinics of western Kenya. Descriptive statistics present accrual patterns and baseline cohort characteristics.</p></sec><sec id="sec003"><title>Results</title><p>Over 15 months, 820 adults enrolled at 7 sites with 86&#x02013;152 enrolled per site. Monthly site enrollment ranged from 2&#x02013;92 participants. Full (100%) informed consent compliance was independently documented. Half (49.9%) had HIV diagnosed through voluntary counseling and testing. Study arms were similar: mostly females (57.6%) aged 37.6 (SD = 9.0) years with low CD4 (166 [SD = 106]) cells/m<sup>3</sup>). Notable proportions had WHO Stage III or IV disease (28.7%), BMI &#x0003c;18.5 kg/m<sup>2</sup> (23.1%), and a history of tuberculosis (5.6%) or were receiving tuberculosis treatment (8.2%) at ART initiation. In the routine VL arm, 407/409 (99.5%) received baseline VL (234,577 SD = 151,055 copies/ml). All participants received lamivudine; 49.8% started zidovudine followed by 38.4% stavudine and 11.8% tenofovir; and, 64.4% received nevirapine as nNRTI (35.6% efavirenz).</p></sec><sec id="sec004"><title>Conclusions</title><p>A RCT can be enrolled successfully in rural, non-research, resource limited, district-level clinics in western Kenya. Many adults presenting for ART have advanced HIV/AIDS, emphasizing the importance of universal HIV testing and linkage-to-care campaigns.</p></sec><sec id="sec005"><title>Trial Registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01791556">NCT01791556</ext-link>
</p></sec></abstract><funding-group><funding-statement>The Clinic-based ART Diagnostic Evaluation (CLADE) trial is sponsored by the U.S. Office of the Global AIDS Coordinator (#KE-07-0044). This work was also supported by a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (DOD). Funding was also received through a cooperative agreement (W81XWH-07-2-0065) between the Kenya Medical Research Institute and the U.S. Department of Defense (DOD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="2"/><page-count count="15"/></counts></article-meta></front><body><sec sec-type="intro" id="sec006"><title>Introduction</title><p>Both CD4+ T-cell count (CD4 count) and plasma HIV-1 RNA (viral load [VL]) are standard of care assessments of immune function and HIV viremia in patients receiving antiretroviral therapy (ART) in resource-rich settings.[<xref rid="pone.0116299.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0116299.ref002" ref-type="bibr">2</xref>] In resource-limited settings such as sub-Saharan Africa where marked advancements have been made in ART roll-out, ART monitoring has been primarily based upon clinical (i.e. World Health Organization [WHO] Stage) and immunological (i.e. CD4 count) evaluations.[<xref rid="pone.0116299.ref003" ref-type="bibr">3</xref>] The poor predictive value of WHO clinical stage and/or CD4 count in identifying virologic failures, however, has been well documented.[<xref rid="pone.0116299.ref004" ref-type="bibr">4</xref>&#x02013;<xref rid="pone.0116299.ref008" ref-type="bibr">8</xref>] 2010 WHO guidelines recommended VL where available every 6 months to evaluate viremia and the use of &#x0201c;confirmatory&#x0201d; VL monitoring for suspected treatment failures. [<xref rid="pone.0116299.ref009" ref-type="bibr">9</xref>] More recently, 2013 WHO guidelines recommend VL as the preferred monitoring approach to diagnose and confirm ART treatment failure (strong recommendation, low-quality evidence). [<xref rid="pone.0116299.ref010" ref-type="bibr">10</xref>] In Kenya, Ministry of Health (MoH) guidelines now recommend &#x0201c;targeted&#x0201d; VL monitoring in effort to assess viremia in cases of suspected clinical or immunological treatment failure.[<xref rid="pone.0116299.ref011" ref-type="bibr">11</xref>]</p><p>With marked advances in ART roll-out in sub-Saharan Africa planned, it is important to evaluate the role of routine VL monitoring.[<xref rid="pone.0116299.ref012" ref-type="bibr">12</xref>&#x02013;<xref rid="pone.0116299.ref014" ref-type="bibr">14</xref>] Despite recent guidelines&#x02019; recommendations for VL monitoring, data regarding VL monitoring in the relevant clinical settings is limited.[<xref rid="pone.0116299.ref009" ref-type="bibr">9</xref>] Primary data from randomized, controlled trials (RCT) including cost-effectiveness will be critical for policy makers in an effort to assure optimal ART monitoring for best short and long-term outcomes in the face of inherent tensions VL monitoring brings with regard to constrained costs, limited infrastructure, and maximizing access. Here, we describe the design, accrual, and baseline characteristics of a RCT designed to evaluate the feasibility, superiority, and cost-effectiveness of routine VL monitoring in predominately rural, district-level ART clinics in Kenya.</p></sec><sec sec-type="materials|methods" id="sec007"><title>Methods</title><sec id="sec008"><title>Study Design</title><p>The <underline>CL</underline>inic-based <underline>A</underline>RT <underline>D</underline>iagnostic <underline>E</underline>valuation (CLADE) study is an open-label RCT evaluating the superiority and cost-effectiveness of two VL monitoring approaches in adults initiating first-line ART: 1. routine care (Arm A) consisting of clinical (WHO staging) and immunological (CD4 count) monitoring every 6 months with confirmatory or targeted VL monitoring based upon Kenya MoH and WHO guidelines standard of care; and 2. VL guided care (Arm B) consisting of VL, CD4 count, and clinical evaluations conducted every 6 months.[<xref rid="pone.0116299.ref015" ref-type="bibr">15</xref>]</p><p>CLADE has two primary objectives: 1. compare proportions of viral failures defined as an HIV-1 RNA VL greater than 1,000 copies/ml after 18 months of follow-up; and 2. evaluate the cost-effectiveness of routine VL monitoring in addition to CD4 and clinical monitoring by measuring actual health outcome costs. The second primary objective, cost-effectiveness, analysis will be based upon actual costs incurred. Analyses will proceed after all follow-up data are available and based upon established methods.[<xref rid="pone.0116299.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="pone.0116299.ref018" ref-type="bibr">18</xref>]. The study includes 12 secondary objectives broadly covering clinical (e.g. disease progression, hospitalization, mortality) and laboratory (e.g. primary and secondary HIV drug resistance and HIV sub-type) secondary endpoints; evaluating differing ART regimens and viral failure criteria; and capacity development with feasibility evaluation of conducting routine VL evaluated by monitoring under a RCT with Good Clinical Practices.</p><p>The CLADE sample size is 820 HIV infected, ART na&#x000ef;ve adults initiating first line ART. Overall, a total of 734 subjects (367 per arm) were required in order to achieve 80% power (alpha = 5%) with a two-sided z-test with continuity correction to test the null hypothesis. Initial sample size parameter estimates were based upon local viral failure rates from a Phase III therapeutics study (&#x0003c;1%) utilizing routine VL monitoring and early field data from ART roll-out (approximately 12%). For the CLADE study designed to evaluate viral failure rates in a non-research setting, a more conservative delta was utilized with probabilities of viral failure in routine care (Arm A) and viral load (Arm B) arms being 8% and 3%, respectively.</p><p>Randomization (1:1) in permuted blocks to arm A or arm B occurred at day of ART initiation at each site using telephone procedures between the site Study Coordinator and data management staff at the Kenya Medical Research Institute/Walter Reed Project (KEMRI/WRP) Clinical Research Center. Randomization was independently verified through data extraction processes and data quality assurance/quality control procedures.</p><p>This sample size allowed for one interim analysis conducted when half of the participants completed the final, 18-month visit and a final analysis at the end of the study using an O&#x02019;Brien-Fleming spending function. The lower and upper boundaries for the interim analysis are z (lower) = -2.96 and z (upper) = 2.96, with a p-value = 0.0031. Two additional inflations were made to the sample size: 5% for lost to follow-up and 5% in anticipation of participants on the routine care arm A receiving confirmatory VL monitoring. This 10% inflation resulted in an overall study sample size of 818.</p><p>Inclusion criteria were: HIV-1 infected adults &#x0003e;18 years old who provided written informed consent and started first line ART based upon Kenya MoH guidelines. Exclusion criteria were: pregnancy at time of ART initiation; any reason (medical, social, or other) the clinic felt would prevent the participant from routine ART follow-up; or, any reason that makes risks of study participation outweigh benefits (e.g. HIV partner non-disclosure and concern over participation in research).</p></sec><sec id="sec009"><title>Study Setting</title><p>CLADE was conducted at 7 district level ART clinics (5 MoH and 2 Faith-based organization [FBO]) in western Kenya&#x02019;s Rift Valley (n = 6) and Nyanza (n = 1) Provinces (<xref rid="pone.0116299.g001" ref-type="fig">Fig. 1</xref>). Over half (51.4%) of all HIV-infected adults in Kenya live in the Rift Valley and Nyanza Provinces based upon the 2007 Kenya AIDS Indicator Survey.[<xref rid="pone.0116299.ref019" ref-type="bibr">19</xref>] Urban and rural HIV prevalence rates among adults from this national survey were 6.3% and 6.4% for Rift Valley Province and 14.9% and 13.9% for Nyanza Province, respectively.[<xref rid="pone.0116299.ref019" ref-type="bibr">19</xref>] Variability in prevalence exists based upon populations studied and methods utilized. HIV-1 prevalence rates were 14.3% from a community-based cohort study and 31.4% in a high risk cohort study based in the Kericho District of the Rift Valley Province.[<xref rid="pone.0116299.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0116299.ref021" ref-type="bibr">21</xref>] Corresponding 12 month HIV incidence rates were 1.4 and 4.0 per 100 person years, respectively.[<xref rid="pone.0116299.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0116299.ref022" ref-type="bibr">22</xref>]</p><fig id="pone.0116299.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0116299.g001</object-id><label>Fig 1</label><caption><title>Participating Sites in the Clinic-based ART Diagnostic Evaluation (CLADE) Trial.</title><p>Map data courtesy of Kenya Open Data (<ext-link ext-link-type="uri" xlink:href="https://opendata.go.ke">https://opendata.go.ke</ext-link>).</p></caption><graphic xlink:href="pone.0116299.g001"/></fig><p>With approximately 70% of Kenya&#x02019;s population being rural, a majority of HIV disease burden is in rural settings.[<xref rid="pone.0116299.ref019" ref-type="bibr">19</xref>, <xref rid="pone.0116299.ref023" ref-type="bibr">23</xref>] All clinics participating in CLADE are in 4 counties of Kenya: Kericho, Nandi, Bomet and Kisumu. While Kericho town has become more densely populated, the county itself and catchment area are 61.3% rural. Nandi county is 86.4% rural, and Bomet county is 85.2% rural. Kisumu county (including Kisumu, Kenya&#x02019;s third largest city) is urban with a rural population of 47.6%, although Kisumu West District Hospital as a participating clinic falls within the Kisumu rural constituency.[<xref rid="pone.0116299.ref023" ref-type="bibr">23</xref>]</p><p>Serving as a regional referral hospital, Kericho District Hospital has an out-patient HIV clinic size of approximately 14,000 patients. Other clinic sizes range from 3,000 to 11,000 HIV infected patients.[<xref rid="pone.0116299.ref024" ref-type="bibr">24</xref>,<xref rid="pone.0116299.ref025" ref-type="bibr">25</xref>] All of the HIV out-patient clinics are staffed primarily by clinical officers and nurses, the primary, health care work force in Kenya. Six of the clinics have medical officers and three have Internal Medicine MMED physicians available for consultation. Each participating site had an existing HIV clinic for 3&#x02013;5 years prior to study opening.[<xref rid="pone.0116299.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0116299.ref025" ref-type="bibr">25</xref>]</p></sec><sec id="sec010"><title>Sponsor, Regulatory Oversight, and Community Advisory Board</title><p>CLADE is sponsored by the U.S. Office of the Global AIDS Coordinator (#KE-07&#x02013;0044), and is a registered clinical trial (registration number NCT01791556).[<xref rid="pone.0116299.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0116299.ref026" ref-type="bibr">26</xref>] The trial was conducted by the Kenya Medical Research Institute/Walter Reed Project (KEMRI/WRP) HIV program in collaboration with the Kenya MoH (now Kenya Ministry of Medical Services) under the auspices of the Kenya Medical Research Institute (KEMRI) and US Military HIV Research Program (MHRP).[<xref rid="pone.0116299.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0116299.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0116299.ref027" ref-type="bibr">27</xref>] Monitoring for GCP compliance was conducted by the MHRP Regulatory Office Center focusing upon regulatory documents, clinic study data, and 100% informed consent review.</p><p>A seven-member, independent Data Monitoring Committee (DMC) consisting of Kenyan (n = 4) and international (n = 3) experts including the KEMRI/WRP Community Advisory Board (CAB) chairman met prior to protocol submission and every six months (+/- 30 days) after the first participant was randomized. The DMC terms of reference included: 1. examine over time the endpoint data and safety signals, including second line therapy switches; and 2. independently review the general progress and conduct of the CLADE study.</p><p>A 13 member, independent CAB oversees and provides guidance on all research and care and treatment activities of the KEMRI/WRP program.</p></sec><sec id="sec011"><title>Ethics Statement</title><p>CLADE had full review and approval by 3 institutional review boards and/or ethics review committees: the Kenya Medical Research Institute, Tenwek Mission Hospital, and Walter Reed Army Institute of Research.[<xref rid="pone.0116299.ref028" ref-type="bibr">28</xref>&#x02013;<xref rid="pone.0116299.ref030" ref-type="bibr">30</xref>] All participants provided written informed consent either in English, Swahili or Dholuo. The latest protocol document approved was version 2.5.</p></sec><sec id="sec012"><title>Study Care</title><p>Care for CLADE participants was in accordance with the standard of care as outlined by the Kenya MoH. The MoH in collaboration with KEMRI/WRP under the United States President&#x02019;s Emergency Plan For AIDS Relief (PEPFAR) program supports HIV care, prevention, and treatment services in the southern Rift Valley Province of Kenya (SRV) with a population of approximately 2.5 million.[<xref rid="pone.0116299.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0116299.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0116299.ref027" ref-type="bibr">27</xref>, <xref rid="pone.0116299.ref031" ref-type="bibr">31</xref>] Beginning with 4 initial HIV treatment sites in 2004, the KEMRI/WRP program coverage now includes 11 district level, primary ART facilities (including 6 of the 7 CLADE sites), 91 lower level facilities (i.e. sub-district hospitals, rural health centers, dispensaries), and over 400 PMTCT sites. The KEMRI/WRP PEPFAR program includes clinical and laboratory program managers and staff as well as an administrative core who support partners in the SRV providing HIV services through PEPFAR funding.</p><p>
<bold>A. HIV Diagnosis and Pre-ART Evaluations.</bold> HIV diagnosis was established by the use of licensed rapid diagnostic tests (RDT) in accordance with HIV Testing and Counseling (HTC) guidelines.[<xref rid="pone.0116299.ref032" ref-type="bibr">32</xref>&#x02013;<xref rid="pone.0116299.ref034" ref-type="bibr">34</xref>] Confirmation of HIV diagnosis was a criteria for study eligibility. Evaluation and preparation for ART included components of an &#x0201c;essential care package&#x0201d; for Persons Living With HIV/AIDS (PLWHA): counseling (HIV and general ART) and psychosocial support; nutritional assessment and supplementation; medical evaluation and WHO staging; laboratory evaluation; and, treatment and prophylaxis of opportunistic infections (OIs).[<xref rid="pone.0116299.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0116299.ref035" ref-type="bibr">35</xref>, <xref rid="pone.0116299.ref036" ref-type="bibr">36</xref>]</p><p>Universal trimethoprim/sulfamethoxazole prophylaxis is used in the region. Screening and prophylaxis for <italic>Cryptococcal</italic> meningitis is conducted in persons with CD4 counts less than 100 cells/mm<sup>3</sup>. Routine screening for Tuberculosis (Tb) is conducted at all sites offering ART, with those suspected of Tb undergoing further diagnostic evaluations based on sputum microscopy and X-ray. Isoniazid preventive therapy (IPT) was being introduced but not routinely conducted at any of the CLADE sites during the study. During pre-ART evaluations, patients were introduced to the CLADE study at participating sites and provided copies of the informed consent. Follow-up discussions with the health care provider and/or site study coordinator were made available.</p><p>
<bold>B. First Line ART and Treatment of Opportunistic Infections.</bold> ART and treatments for OIs and non-HIV related illness were based upon national guidelines.[<xref rid="pone.0116299.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0116299.ref035" ref-type="bibr">35</xref>&#x02013;<xref rid="pone.0116299.ref038" ref-type="bibr">38</xref>] Initially, ART criteria included all patients with WHO Stage III or IV disease as well as those with WHO Stage I or II and a CD4 count less <underline>&#x0003c;</underline> 250 cells/mm<sup>3</sup>.[<xref rid="pone.0116299.ref035" ref-type="bibr">35</xref>] With newer guidelines, ART was recommended for all patients with a CD4 count <underline>&#x0003c;</underline> 350 cells/mm<sup>3</sup> or in those &#x0003e; 350 cells/mm<sup>3</sup> with Mycobacterium tuberculosis (Tb), HIV/Hepatitis B virus (HBV) co-infection, or HIV nephropathy.[<xref rid="pone.0116299.ref011" ref-type="bibr">11</xref>] First line ART consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitors (nNRTI): stavudine or zidovudine, lamivudine, and nevirapine or efavirenz. This changed when tenofovir became available and stavudine was removed from first line recommendations.[<xref rid="pone.0116299.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0116299.ref011" ref-type="bibr">11</xref>]</p><p>
<bold>C. Laboratory Evaluations.</bold> All participating sites conducted MoH recommended ART safety evaluations (alanine aminotransferase/aspartate aminotransferase, creatinine, hemoglobin), and several were capable of more extensive chemistries and hematology tests, and urine pregnancy testing. In addition, sites conducted evaluations for co-infections including but not limited to microscopy for sputum acid fast bacilli and malaria blood parasites, cryptococcal antigen testing and Indian Ink, and hepatitis B serology. Five laboratories performed CD4 count evaluations with two sites relying upon local partner sites (Nandi Hills and Litein relying upon Kapsabet and Kapkatet, respectively). All laboratories were enrolled in External Quality Assurance (EQA programs through Human Quality Assessment Services (HuQAS) conducted quarterly.[<xref rid="pone.0116299.ref039" ref-type="bibr">39</xref>]</p><p>The KEMRI/WRP CRC laboratory conducts HIV-1 RNA (VL) testing for all clinics in the SRV program and serves as a back-up laboratory when needed. The Roche Amplicor v1.5 was used for VL testing. The Abbott m2000 system and Roche Taqman were used for back-up. Plasma separator preparation tubes were used for storage and transport of VL specimens to the central laboratory within 24 hours for all sites except for Kericho District Hospital where samples were delivered immediately. The KEMRI/WRP laboratory is enrolled in numerous EQA programs and maintains College of American Pathologist (CAP) accreditation (2008, 2010, and 2012).[<xref rid="pone.0116299.ref040" ref-type="bibr">40</xref>]</p></sec><sec id="sec013"><title>Capacity Development</title><p>Key secondary objectives of CLADE focused upon the development of local capacity to incorporate VL monitoring consistent with newer guidelines and improve treatment failure competency. &#x0201c;Treatment failure retreats&#x0201d; were held at least bi-annually with all regional HIV programs. Expert lectures were incorporated. Cognizant of the need for research conducted outside of the traditional research setting and in response to requests for capacity development by the MoH partners, clinical research capacity was developed at each site. General research conduct and GCP were taught with each site having a dedicated Study Coordinator completing human research subjects training.[<xref rid="pone.0116299.ref041" ref-type="bibr">41</xref>] Finally, the Data Manager (PY) with a BS in Computer Science was sponsored by the study for enrollment in the University of Nairobi Medical Statistics Masters degree program with project work tied to secondary objective analysis (early morbidity and mortality).</p></sec><sec id="sec014"><title>Study Data and Analyses</title><p>Study participants had a study folder kept at the ART clinic in a locked filing cabinet with access limited to study staff. The CLADE study folder consisted of case report forms (CRFs) mirroring the participant&#x02019;s clinical record with data extracted as necessary for study analyses. Based upon concerns shared by MoH and FBO partners regarding the time and burden related to collection of study data for this first of its kind clinical trial, two tiers of CRFs were utilized: primary CRFs that included data linked to human subjects protection/GCP and key study objectives including the primary endpoint, for which 100% data capture was expected; and, secondary CRFs that included data captured by the clinic but not essential to the study objectives or primary endpoint (e.g. other clinical laboratory data, demographics), for which 100% was the goal but not absolute. The CLADE study folder had no personal identifying information. The folder was identified by the patient clinic &#x0201c;HAART&#x0201d; number (assigned at all clinics sequentially as patients entered clinics) and 4-digit random Subject Identification Number. All study procedures, including data collection, were conducted under study specific Standard Operating Procedures (SOPs).</p><p>Procedurally, extraction of relevant clinic data and population of the study database occurred in 3 steps. First, relevant data were recorded on visit Case Report Forms (CRFs) at the time of routine HIV clinic evaluations. Second, every 2 weeks or at a frequency necessary depending upon site accrual, members of the IT data team reported to study sites to enter CRF data onto password protected study laptops with 128-bit encryption. Finally, data was downloaded to the database at the KEMRI/WRP CRC IT Department daily or at a frequency no greater than once weekly. After central data download, laptop data was erased. No identifying information was kept on the CLADE laptops.</p><p>The study database, created and maintained by KEMRI/WRP IT staff, is a relational database management system (RDBMS) with integrated data management and analysis software. The application was a single entry system with programmed logic checks and prompts. The CLADE database is stored on a password protected, secured folder on the CRC research servers. All CLADE data is managed and analyzed in Kenya at the KEMRI/WRP CRC IT Department. For accrual and baseline enrollment data presented, routine, descriptive summary statistics are used. Analyses for data presented here are conducted in Kericho on the database locked January 31, 2013 with statistical validation by EmpiriStat.</p></sec></sec><sec sec-type="results" id="sec015"><title>Results</title><sec id="sec016"><title>Enrollment</title><p>Beginning in January 2010, 820 adults initiating ART were enrolled at 7 sites with 86&#x02013;152 enrolled per site (<xref rid="pone.0116299.t001" ref-type="table">Table 1</xref>). Time for accrual at each site ranged from 6.6&#x02013;11.2 months. Three site allocation adjustments were made throughout the enrollment period with sites finally enrolling a range of 71%-133% of their initial allocations. Full enrollment was accomplished in 15 months with monthly accrual ranging from 2 (first site activated) to 92 (all sites activated) participants (<xref rid="pone.0116299.g002" ref-type="fig">Fig. 2</xref>).</p><table-wrap id="pone.0116299.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0116299.t001</object-id><label>Table 1</label><caption><title>Participant Recruitment and Accrual in the Clinic-based ART Diagnostic Evaluation Trial (CLADE).</title></caption><alternatives><graphic id="pone.0116299.t001g" xlink:href="pone.0116299.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Site</th><th align="left" rowspan="1" colspan="1">Start Date</th><th align="left" rowspan="1" colspan="1">Months of Accrual</th><th align="left" rowspan="1" colspan="1">Initial Allocation</th><th align="left" rowspan="1" colspan="1">Final Allocation</th><th align="left" rowspan="1" colspan="1">Average Enrollment/Month</th><th align="left" rowspan="1" colspan="1">Percentage of Initial Allocation</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>AIC Litein Mission Hospital</bold>
</td><td align="left" rowspan="1" colspan="1">February 26, 2010</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">86</td><td align="char" char="." rowspan="1" colspan="1">6.6</td><td align="left" rowspan="1" colspan="1">96%</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Kapkatet District Hospital</bold>
</td><td align="left" rowspan="1" colspan="1">January 26, 2010</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">120</td><td align="char" char="." rowspan="1" colspan="1">8.5</td><td align="left" rowspan="1" colspan="1">133%</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Kapsabet District Hospital</bold>
</td><td align="left" rowspan="1" colspan="1">February 16, 2010</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">110</td><td align="left" rowspan="1" colspan="1">124</td><td align="char" char="." rowspan="1" colspan="1">9.5</td><td align="left" rowspan="1" colspan="1">113%</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Kericho District Hospital</bold>
</td><td align="left" rowspan="1" colspan="1">January 28, 2010</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">150</td><td align="left" rowspan="1" colspan="1">152</td><td align="char" char="." rowspan="1" colspan="1">10.8</td><td align="left" rowspan="1" colspan="1">101%</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Kisumu West District Hospital</bold>
</td><td align="left" rowspan="1" colspan="1">March 8, 2010</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">190</td><td align="left" rowspan="1" colspan="1">134</td><td align="char" char="." rowspan="1" colspan="1">11.2</td><td align="left" rowspan="1" colspan="1">71%</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Nandi Hills District Hospital</bold>
</td><td align="left" rowspan="1" colspan="1">March 3, 2010</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">110</td><td align="char" char="." rowspan="1" colspan="1">9.2</td><td align="left" rowspan="1" colspan="1">122%</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Tenwek Mission Hospital</bold>
</td><td align="left" rowspan="1" colspan="1">May 21, 2010</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">94</td><td align="char" char="." rowspan="1" colspan="1">9.4</td><td align="left" rowspan="1" colspan="1">94%</td></tr></tbody></table></alternatives></table-wrap><fig id="pone.0116299.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0116299.g002</object-id><label>Fig 2</label><caption><title>Participant Enrollment by Month in the CLinic-based ART Diagnostic Evaluation (CLADE) Trial (n = 820).</title></caption><graphic xlink:href="pone.0116299.g002"/></fig></sec><sec id="sec017"><title>Baseline Characteristics</title><p>The 2 study arms were similar at baseline (<xref rid="pone.0116299.t002" ref-type="table">Table 2</xref>). Overall, the baseline cohort represented mostly females (57.6%), aged 37.6 (SD = 9.0) years with advanced disease evidenced by low CD4 count (166 SD = 106.5 cells/m<sup>3</sup>) and high HIV-1 RNA (Arm B: 234,577 SD = 151,055copies/ml). Notable proportions had WHO Stage III or IV disease (28.7%), BMI &#x0003c;18.5 kg/m<sup>2</sup> (23.1%), and ongoing Tb treatment at time of ART initiation (8.2%). While not reaching statistic significance, there was a trend in more participants in the routine care arm (7.1%) reporting a history of Tb compared to the VL arm (4.2%) (p = 0.07). Half (49.9%) received HIV testing through established client-initiated, voluntary counseling and testing (VCT) sites. Roughly half had HIV diagnosis established through provider initiated testing and counseling (PITC). The majority (91.5%) received primary (grades 1&#x02013;8) or secondary (grades 9&#x02013;12) education. Over half were married and in monogamous marriages (54.0%) with a small but notable proportion as known, discordant couples (7.2%). Half (54.3%) were unaware of their partner&#x02019;s HIV status. Nearly all had normal or Grade I hemoglobin, liver function (AST/ALT) and renal function (creatinine).</p><p>There were no differences in ART initiated between the two arms. With all beginning ART receiving lamivudine as part of the dual NRTI backbone, about half (49.8%) started zidovudine followed by a slightly smaller proportion (38.4%) beginning stavudine as tenofovir was introduced as first line (11.8%). The majority (64.4%) received nevirapine as the nNRTI. Nearly all (97.3%) received trimethoprim/sulfamethoxazole prophylaxis. Few (8.3%) were receiving concurrent treatment for Tb.</p><table-wrap id="pone.0116299.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0116299.t002</object-id><label>Table 2</label><caption><title>Baseline Characteristics of the CLinic-based ART Diagnostic Evaluation (CLADE) Trial Participants.</title></caption><alternatives><graphic id="pone.0116299.t002g" xlink:href="pone.0116299.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Overall(n = 818)</th><th align="left" rowspan="1" colspan="1">Routine Care(Arm A)n = 409</th><th align="left" rowspan="1" colspan="1">Viral Load Guided Care (Arm B)n = 409</th><th align="left" rowspan="1" colspan="1">Missing Data</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Gender</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Male</bold>
</td><td align="left" rowspan="1" colspan="1">347 (42.4%)</td><td align="left" rowspan="1" colspan="1">172 (42.1%)</td><td align="left" rowspan="1" colspan="1">175 (42.8%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Female</bold>
</td><td align="left" rowspan="1" colspan="1">471 (57.6%)</td><td align="left" rowspan="1" colspan="1">237 (57.9%)</td><td align="left" rowspan="1" colspan="1">234 (57.2%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age (years)</bold>
</td><td align="left" rowspan="1" colspan="1">37.6 (9.0)</td><td align="left" rowspan="1" colspan="1">37.5 (8.9)</td><td align="left" rowspan="1" colspan="1">37.8 (9.1)</td><td align="left" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>CD4 count (cells/mm<sup>3</sup>)</bold>
</td><td align="left" rowspan="1" colspan="1">166 (106.5)</td><td align="left" rowspan="1" colspan="1">164 (109.3)</td><td align="left" rowspan="1" colspan="1">168 (103.6)</td><td align="left" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c; = 50</bold>
</td><td align="left" rowspan="1" colspan="1">143 (17.5%)</td><td align="left" rowspan="1" colspan="1">76 (18.6%)</td><td align="left" rowspan="1" colspan="1">67 (16.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>51&#x02013;199</bold>
</td><td align="left" rowspan="1" colspan="1">362 (44.3%)</td><td align="left" rowspan="1" colspan="1">173 (42.3%)</td><td align="left" rowspan="1" colspan="1">189 (46.2%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>200&#x02013;349</bold>
</td><td align="left" rowspan="1" colspan="1">293 (35.8%)</td><td align="left" rowspan="1" colspan="1">148 (36.2%)</td><td align="left" rowspan="1" colspan="1">145 (35.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x0003e; = 350</bold>
</td><td align="left" rowspan="1" colspan="1">20 (2.4%)</td><td align="left" rowspan="1" colspan="1">12 (2.9%)</td><td align="left" rowspan="1" colspan="1">8 (2.0%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>HIV-1 RNA (copies/ml)</bold>
</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">234,577 (151,055)</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>WHO Stage</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">8 (0.97%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>I</bold>
</td><td align="left" rowspan="1" colspan="1">302 (37.3%)</td><td align="left" rowspan="1" colspan="1">145 (35.9%)</td><td align="left" rowspan="1" colspan="1">157 (38.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>II</bold>
</td><td align="left" rowspan="1" colspan="1">275 (33.9%)</td><td align="left" rowspan="1" colspan="1">135 (33.4%)</td><td align="left" rowspan="1" colspan="1">140 (34.5%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>III</bold>
</td><td align="left" rowspan="1" colspan="1">202 (24.9%)</td><td align="left" rowspan="1" colspan="1">108 (26.7%)</td><td align="left" rowspan="1" colspan="1">94 (23.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>IV</bold>
</td><td align="left" rowspan="1" colspan="1">31 (3.8%)</td><td align="left" rowspan="1" colspan="1">16 (4.0%)</td><td align="left" rowspan="1" colspan="1">15 (3.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Body Mass Index (kg/m</bold>
<sup><bold>2</bold></sup>
<bold>)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">12 (1.47%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;16</bold>
</td><td align="left" rowspan="1" colspan="1">40 (5.0%)</td><td align="left" rowspan="1" colspan="1">25 (6.2%)</td><td align="left" rowspan="1" colspan="1">15 (3.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>16 - &#x0003c;18.5</bold>
</td><td align="left" rowspan="1" colspan="1">146 (18.1%)</td><td align="left" rowspan="1" colspan="1">75 (18.6%)</td><td align="left" rowspan="1" colspan="1">71 (17.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>18.5 - &#x0003c; 25</bold>
</td><td align="left" rowspan="1" colspan="1">507 (62.9%)</td><td align="left" rowspan="1" colspan="1">251 (62.1%)</td><td align="left" rowspan="1" colspan="1">256 (63.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>25 - &#x0003c; 30</bold>
</td><td align="left" rowspan="1" colspan="1">91 (11.3%)</td><td align="left" rowspan="1" colspan="1">41 (10.1%)</td><td align="left" rowspan="1" colspan="1">50 (12.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x02265; 30</bold>
</td><td align="left" rowspan="1" colspan="1">22 (2.7%)</td><td align="left" rowspan="1" colspan="1">12 (3.0%)</td><td align="left" rowspan="1" colspan="1">10 (2.5%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Counseling &#x00026; Testing/Point of Entry</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>VCT</bold>
</td><td align="left" rowspan="1" colspan="1">408 (49.9%)</td><td align="left" rowspan="1" colspan="1">207 (50.6%)</td><td align="left" rowspan="1" colspan="1">201 (49.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>PITC</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>DTC</italic></bold>
</td><td align="left" rowspan="1" colspan="1">126 (15.4%)</td><td align="left" rowspan="1" colspan="1">64 (15.6%)</td><td align="left" rowspan="1" colspan="1">62 (15.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>OPD</italic></bold>
</td><td align="left" rowspan="1" colspan="1">83 (10.1%)</td><td align="left" rowspan="1" colspan="1">39 (9.5%)</td><td align="left" rowspan="1" colspan="1">44 (10.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>In-patient Wards</italic></bold>
</td><td align="left" rowspan="1" colspan="1">71 (8.7%)</td><td align="left" rowspan="1" colspan="1">34 (8.3%)</td><td align="left" rowspan="1" colspan="1">37 (9.0%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>PMTCT</italic></bold>
</td><td align="left" rowspan="1" colspan="1">16 (1.9%)</td><td align="left" rowspan="1" colspan="1">8 (1.9%)</td><td align="left" rowspan="1" colspan="1">8 (1.9%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Tb Clinic</italic></bold>
</td><td align="left" rowspan="1" colspan="1">11 (1.3%)</td><td align="left" rowspan="1" colspan="1">4 (1.0%)</td><td align="left" rowspan="1" colspan="1">7 (1.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold><italic>Other PITC</italic></bold>
</td><td align="left" rowspan="1" colspan="1">62 (7.6%)</td><td align="left" rowspan="1" colspan="1">31 (7.6%)</td><td align="left" rowspan="1" colspan="1">31 (7.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Other</bold>
</td><td align="left" rowspan="1" colspan="1">41 (5.0%)</td><td align="left" rowspan="1" colspan="1">22 (5.4%)</td><td align="left" rowspan="1" colspan="1">19 (4.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Education Level</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>None</bold>
</td><td align="left" rowspan="1" colspan="1">21 (2.6%)</td><td align="left" rowspan="1" colspan="1">8 (1.9%)</td><td align="left" rowspan="1" colspan="1">13 (3.2%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Primary</bold>
</td><td align="left" rowspan="1" colspan="1">457 (55.9%)</td><td align="left" rowspan="1" colspan="1">239 (58.4%)</td><td align="left" rowspan="1" colspan="1">218 (53.3%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Secondary</bold>
</td><td align="left" rowspan="1" colspan="1">291 (35.6%)</td><td align="left" rowspan="1" colspan="1">136 (33.2%)</td><td align="left" rowspan="1" colspan="1">155 (37.9%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Tertiary</bold>
</td><td align="left" rowspan="1" colspan="1">49 (6.0%)</td><td align="left" rowspan="1" colspan="1">26 (6.4%)</td><td align="left" rowspan="1" colspan="1">23 (5.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Marital Status</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Single</bold>
</td><td align="left" rowspan="1" colspan="1">94 (11.5%)</td><td align="left" rowspan="1" colspan="1">45 (11.0%)</td><td align="left" rowspan="1" colspan="1">49 (11.9%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Married monogamous</bold>
</td><td align="left" rowspan="1" colspan="1">442 (54.0%)</td><td align="left" rowspan="1" colspan="1">230 (56.2%)</td><td align="left" rowspan="1" colspan="1">212 (51.8%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Married polygamous</bold>
</td><td align="left" rowspan="1" colspan="1">66 (8.1%)</td><td align="left" rowspan="1" colspan="1">33 (8.1%)</td><td align="left" rowspan="1" colspan="1">33 (8.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Cohabitating</bold>
</td><td align="left" rowspan="1" colspan="1">29 (3.6%)</td><td align="left" rowspan="1" colspan="1">16 (3.9%)</td><td align="left" rowspan="1" colspan="1">13 (3.2%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Separated</bold>
</td><td align="left" rowspan="1" colspan="1">70 (8.6%)</td><td align="left" rowspan="1" colspan="1">31 (7.6%)</td><td align="left" rowspan="1" colspan="1">39 (9.5%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Divorced</bold>
</td><td align="left" rowspan="1" colspan="1">10 (1.2%)</td><td align="left" rowspan="1" colspan="1">6 (1.5%)</td><td align="left" rowspan="1" colspan="1">4 1.0%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Widowed</bold>
</td><td align="left" rowspan="1" colspan="1">107 (13.1%)</td><td align="left" rowspan="1" colspan="1">48 (11.7%)</td><td align="left" rowspan="1" colspan="1">59 (14.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Discordant Couple</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yes</bold>
</td><td align="left" rowspan="1" colspan="1">59 (7.2%)</td><td align="left" rowspan="1" colspan="1">27 (6.6%)</td><td align="left" rowspan="1" colspan="1">32 (7.8%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>No</bold>
</td><td align="left" rowspan="1" colspan="1">315 (38.5%)</td><td align="left" rowspan="1" colspan="1">156 (38.1%)</td><td align="left" rowspan="1" colspan="1">159 (38.8%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Unknown</bold>
</td><td align="left" rowspan="1" colspan="1">444 (54.3%)</td><td align="left" rowspan="1" colspan="1">226 (55.2%)</td><td align="left" rowspan="1" colspan="1">218 (53.3%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>History of Tb Treatment</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yes</bold>
</td><td align="left" rowspan="1" colspan="1">46 (5.6%)</td><td align="left" rowspan="1" colspan="1">29 (7.1%)</td><td align="left" rowspan="1" colspan="1">17 (4.2%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>No</bold>
</td><td align="left" rowspan="1" colspan="1">763 (93.3%)</td><td align="left" rowspan="1" colspan="1">374 (91.4%)</td><td align="left" rowspan="1" colspan="1">389 (95.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Unknown</bold>
</td><td align="left" rowspan="1" colspan="1">9 (1.1%)</td><td align="left" rowspan="1" colspan="1">6 (1.5%)</td><td align="left" rowspan="1" colspan="1">3 (0.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>History of Cryptococcus Treatment</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yes</bold>
</td><td align="left" rowspan="1" colspan="1">3 (0.4%)</td><td align="left" rowspan="1" colspan="1">2 (0.5%)</td><td align="left" rowspan="1" colspan="1">1 (0.3%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>No</bold>
</td><td align="left" rowspan="1" colspan="1">806 (98.5%)</td><td align="left" rowspan="1" colspan="1">401(98.0%)</td><td align="left" rowspan="1" colspan="1">405 (99.0%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Unknown</bold>
</td><td align="left" rowspan="1" colspan="1">9 (1.1%)</td><td align="left" rowspan="1" colspan="1">6 (1.5%)</td><td align="left" rowspan="1" colspan="1">3 (0.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Current TMP/SMX prophylaxis</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yes</bold>
</td><td align="left" rowspan="1" colspan="1">796 (97.3%)</td><td align="left" rowspan="1" colspan="1">396 (96.8%)</td><td align="left" rowspan="1" colspan="1">400 (97.8%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>No</bold>
</td><td align="left" rowspan="1" colspan="1">9 (1.1%)</td><td align="left" rowspan="1" colspan="1">6 (1.5%)</td><td align="left" rowspan="1" colspan="1">3 (0.7%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Unknown</bold>
</td><td align="left" rowspan="1" colspan="1">13 (1.6%)</td><td align="left" rowspan="1" colspan="1">7 (1.7%)</td><td align="left" rowspan="1" colspan="1">6 (1.5%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Current Tb Treatment</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Yes</bold>
</td><td align="left" rowspan="1" colspan="1">67 (8.2%)</td><td align="left" rowspan="1" colspan="1">36 (8.8%)</td><td align="left" rowspan="1" colspan="1">31 (7.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>No</bold>
</td><td align="left" rowspan="1" colspan="1">738 (90.2%)</td><td align="left" rowspan="1" colspan="1">366 (89.5%)</td><td align="left" rowspan="1" colspan="1">372 (90.9%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Unknown</bold>
</td><td align="left" rowspan="1" colspan="1">13 (1.6%)</td><td align="left" rowspan="1" colspan="1">7 (1.7%)</td><td align="left" rowspan="1" colspan="1">6 (1.5%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>HgB (g/dL)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">161 (19.68%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 0 /Normal</bold>
</td><td align="left" rowspan="1" colspan="1">467 (71.4%)</td><td align="left" rowspan="1" colspan="1">239 (73.3%)</td><td align="left" rowspan="1" colspan="1">228 (69.5%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 1</bold>
</td><td align="left" rowspan="1" colspan="1">129 (19.7%)</td><td align="left" rowspan="1" colspan="1">58 (17.8%)</td><td align="left" rowspan="1" colspan="1">71 (21.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 2</bold>
</td><td align="left" rowspan="1" colspan="1">30 (4.6%)</td><td align="left" rowspan="1" colspan="1">15 (4.6%)</td><td align="left" rowspan="1" colspan="1">15 (4.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 3</bold>
</td><td align="left" rowspan="1" colspan="1">15 (2.3%)</td><td align="left" rowspan="1" colspan="1">9 (2.8%)</td><td align="left" rowspan="1" colspan="1">6 (1.8%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 4</bold>
</td><td align="left" rowspan="1" colspan="1">13 (2.0%)</td><td align="left" rowspan="1" colspan="1">5 (1.5%)</td><td align="left" rowspan="1" colspan="1">8 (2.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ALT/AST</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">173 (21.15%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 0 /Normal</bold>
</td><td align="left" rowspan="1" colspan="1">618 (95.8%)</td><td align="left" rowspan="1" colspan="1">302 (95.0%)</td><td align="left" rowspan="1" colspan="1">316 (96.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 1</bold>
</td><td align="left" rowspan="1" colspan="1">21 (3.3%)</td><td align="left" rowspan="1" colspan="1">12 (3.8%)</td><td align="left" rowspan="1" colspan="1">9 (2.8%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 2</bold>
</td><td align="left" rowspan="1" colspan="1">6 (0.9%)</td><td align="left" rowspan="1" colspan="1">4 (1.2%)</td><td align="left" rowspan="1" colspan="1">2 (0.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 3</bold>
</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 4</bold>
</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Creatinine (u mol/L)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">161 (19.68%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 0 /Normal</bold>
</td><td align="left" rowspan="1" colspan="1">564 (88.5%)</td><td align="left" rowspan="1" colspan="1">282 (89.5%)</td><td align="left" rowspan="1" colspan="1">282 (87.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 1</bold>
</td><td align="left" rowspan="1" colspan="1">30 (4.7%)</td><td align="left" rowspan="1" colspan="1">13 (4.1%)</td><td align="left" rowspan="1" colspan="1">17 (5.3%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 2</bold>
</td><td align="left" rowspan="1" colspan="1">24 (3.8%)</td><td align="left" rowspan="1" colspan="1">11 (3.5%)</td><td align="left" rowspan="1" colspan="1">13 (4.0%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 3</bold>
</td><td align="left" rowspan="1" colspan="1">15 (2.4%)</td><td align="left" rowspan="1" colspan="1">8 (2.5%)</td><td align="left" rowspan="1" colspan="1">7 (2.2%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Grade 4</bold>
</td><td align="left" rowspan="1" colspan="1">4 (0.6%)</td><td align="left" rowspan="1" colspan="1">1 (0.3%)</td><td align="left" rowspan="1" colspan="1">3 (0.9%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ART Regimen Initiated</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>D4T/3TC/NVP</bold>
</td><td align="left" rowspan="1" colspan="1">234 (28.6%)</td><td align="left" rowspan="1" colspan="1">118 (28.8%)</td><td align="left" rowspan="1" colspan="1">116 (28.4%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>D4T/3TC/EFV</bold>
</td><td align="left" rowspan="1" colspan="1">80 (9.8%)</td><td align="left" rowspan="1" colspan="1">44 (10.8%)</td><td align="left" rowspan="1" colspan="1">36 (8.8%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>AZT/3TC/NVP</bold>
</td><td align="left" rowspan="1" colspan="1">245 (30.0%)</td><td align="left" rowspan="1" colspan="1">120 (29.3%)</td><td align="left" rowspan="1" colspan="1">125 (30.6%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>AZT/3TC/EFV</bold>
</td><td align="left" rowspan="1" colspan="1">162 (19.8%)</td><td align="left" rowspan="1" colspan="1">81 (19.8%)</td><td align="left" rowspan="1" colspan="1">81(19.8%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TDF/3TC/NVP</bold>
</td><td align="left" rowspan="1" colspan="1">47 (5.7%)</td><td align="left" rowspan="1" colspan="1">22 (5.4%)</td><td align="left" rowspan="1" colspan="1">25 (6.1%)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TDF/3TC/EFV</bold>
</td><td align="left" rowspan="1" colspan="1">50 (6.0%)</td><td align="left" rowspan="1" colspan="1">24 (5.9%)</td><td align="left" rowspan="1" colspan="1">26 (6.4%)</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Notes:</p></fn><fn id="t002fn002"><p>1. Data presented as mean (SD) or n (%)</p></fn><fn id="t002fn003"><p>2. Two participants who were randomized but did not continue ART are excluded.</p></fn><fn id="t002fn004"><p>3. Categorical grades based upon the DAIDS Toxicity tables: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening</p></fn><fn id="t002fn005"><p>4. Abbreviations: VCT = Voluntary Counseling and Testing, DTC = Diagnostic Testing and Counseling, PITC = Provider Initiated Testing and Counseling; Tb = tuberculosis, PMTCT = Prevention of Mother to Child Transmission, TMP/SMX = trimethoprim/sulfamethoxazole, D4T = stavudine, 3TC = lamivudine, NVP = nevirapine, EFV = efavirenz, AZT = zidovudine, TDF = tenofovir</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec018"><title>Monitoring and Data Quality</title><p>Prior to full study accrual, the DMC met 3 times with no data or safety concerns. In addition, each site was monitored at least once with 100% informed consent review. Through enrollment and full accrual, 100% informed consent compliance was documented and two protocol violations occurred. During a period of new guidelines being introduced, two participants (0.2%) started ART with higher CD4 counts who did not meet MoH guidelines but were enrolled and ineligible. Both had ART discontinued, continued routine clinic follow-up and including trimethoprim/sulfamethoxazole prophylaxis and multivitamin supplementation and were excluded from analysis.</p><p>Complete baseline CD4+ T-cell and VL (Arm B only) data were obtained and available. At enrollment, all Arm A participants had VLs received in the lab for protocol-defined retrospective analyses. Throughout enrollment, all sites passed quarterly CD4+/CD3+ T cell count external quality assurance (EQA) testing. While one site failed 2 successive EQA tests, it was discovered upon corrective action review that the site transcribed results on the EQA report incorrectly (i.e. CD4+ for CD3+ and vice-versa) and had actually passed after correcting for transcription error. Capture of data linked to secondary CRFs (e.g. aminotransferase/aspartate aminotransferase, hemoglobin, and creatinine) was approximately 80%.</p></sec></sec><sec sec-type="conclusions" id="sec019"><title>Discussion</title><p>The CLADE trial demonstrates a RCT can be designed and fully enrolled under current Good Clinical Practices (GCP) in a predominately rural, resource limited setting by leveraging upon local capacity and infrastructure. For best generalizability regarding the feasibility, superiority, and cost-effectiveness of routine VL monitoring, the question must be studied in the most relevant clinic setting. Limitations in extrapolating findings generated within the context of a research setting are well described in resource rich settings based upon the differences in care[<xref rid="pone.0116299.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0116299.ref043" ref-type="bibr">43</xref>] The magnitude of research vs. clinic setting differences are most likely greater in resource limited settings. CLADE provides a clinical trial model for consideration as the role of implementation science expands under PEPFAR and other donor programs.[<xref rid="pone.0116299.ref044" ref-type="bibr">44</xref>]</p><p>Data generated from the baseline cohort provide unique information and important opportunities for prevention, care, and treatment interventions. To our knowledge, CLADE offers among the first clinical trial data systematically collected in rural, non-research clinics of Kenya. Furthermore, approximately five years after care and treatment programs were implemented, adults presenting for first line ART have notably advanced HIV/AIDS. Half of those asked regarding the HIV status of their partner reported that they were unaware. These findings emphasize the importance of continued universal HIV testing and linkage to care campaigns as well as couples HIV counseling and sharing of HIV status.</p><p>The greatest strengths of CLADE are the design (providing among the strongest quality of data/evidence) and setting (non-research, clinic-based, largely rural where a notable HIV burden exists). With such a RCT never being conducted in rural Kenya (and likely elsewhere in sub-Saharan Africa) before, questions existed regarding the feasibility and practicality of conducting CLADE in non-research, rural, district level facilities. We note evaluating the feasibility of conducting such a trial in this setting was a secondary objective. Concerns related to Good Clinical Practice (GCP) such as informed consent, randomization, and data quality as well as others were found not to be troublesome in the accrual and baseline enrollment. In addition, CLADE has been from its concept largely &#x0201c;owned&#x0201d; by Kenyans with a secondary, supportive role from non-national team members. Last, CLADE leverages largely upon local capacity and infrastructure with strong &#x0201c;buy-in&#x0201d; and support from the MoH, faith-based institutions, and CAB, which should be an expected norm for such research.</p><p>The primary limitation is the inability to draw conclusions regarding secondary endpoints including mortality. By design, the CLADE sample size focuses upon the question of superiority routine VL monitoring. We believed that routine viral monitoring would identify patients with detectable viral loads earlier than immunologic and clinical monitoring resulting in earlier adherence interventions ultimately resulting in more long standing viral suppression. We felt 18 months follow-up (3 series of 6 month routine viral load monitoring) was clinically relevant for comparing routine care versus viral load monitoring. It is appreciated that results from secondary endpoints such as mortality will be largely descriptive in nature. Therefore, CLADE will not be able to draw conclusions regarding the relationships between routine VL monitoring and death. However, the relationship between viral failure and subsequent morbidity and mortality is well established.[<xref rid="pone.0116299.ref045" ref-type="bibr">45</xref>, <xref rid="pone.0116299.ref046" ref-type="bibr">46</xref>] While nearly all data related to the primary objectives and VL endpoint (e.g. CD4 count, VL &#x0003e;98%) were collected, we captured a smaller proportion (approximately 80%) for clinical laboratory evaluations. This reflected the &#x0201c;secondary&#x0201d; data collection approach agreed upon in planning with MoH and FBO implementing partners and suggests the need for additional dedicated staff and funding for future clinic-based clinical trials in such settings.</p><p>While CLADE is unique in methods utilized, additional trials evaluating HIV monitoring approaches in differing populations and settings in Africa exist [<xref rid="pone.0116299.ref047" ref-type="bibr">47</xref>&#x02013;<xref rid="pone.0116299.ref050" ref-type="bibr">50</xref>]. All are important in providing data to inform stakeholders developing future policies and guidelines.</p><p>In conclusion, CLADE provides important experience and data regarding the design and successful enrollment of a RCT under GCP in a rural, non-research, resource limited setting. Important opportunities exist for prevention, care, and treatment programs. Key information to come for clinical care and research programs as well as policy makers will be feasibility, superiority, and cost implications of routine VL monitoring.</p></sec><sec sec-type="supplementary-material" id="sec020"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0116299.s001"><label>S1 CONSORT Checklist</label><caption><title>CLADE Consort Checklist.</title><p>(DOCX)</p></caption><media xlink:href="pone.0116299.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0116299.s002"><label>S1 CONSORT Diagram</label><caption><title>CLADE Consort Diagram.</title><p>(TIF)</p></caption><media xlink:href="pone.0116299.s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0116299.s003"><label>S1 Consent</label><caption><title>CLADE ENGLISH ICF_v 2&#x02013;0 13-February 2012.</title><p>(PDF)</p></caption><media xlink:href="pone.0116299.s003.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0116299.s004"><label>S2 Consent</label><caption><title>CLADE KISWAHILI ICF_v 2&#x02013;0 13-Feb 2012.</title><p>(PDF)</p></caption><media xlink:href="pone.0116299.s004.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0116299.s005"><label>S3 Consent</label><caption><title>CLADE DHOLUO ICF v 2_13 February 2012.</title><p>(PDF)</p></caption><media xlink:href="pone.0116299.s005.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0116299.s006"><label>S1 Protocol</label><caption><title>CLADE Protocol v2&#x02013;5_30NOV12.</title><p>(PDF)</p></caption><media xlink:href="pone.0116299.s006.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0116299.s007"><label>S1 Appendices</label><caption><title>CLADE Appendices 30_Nov_2012.</title><p>(PDF)</p></caption><media xlink:href="pone.0116299.s007.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The CLADE team would like to acknowledge individuals who contributed early in study concept and protocol development including Dr. Mary Marovich, Dr. Hellen Mutai, Dr. George Nyale, and Dr. Clement Zeh. Particular appreciation is given to the dedicated study coordinators at the participating sites: Joan Kapkia, Victoria Chelangat, Joshua Rotich, Zeddy Bett, Janet Ngeno, Linner Rotich, Wesley Maiyo, Enock Changwony, Janet Sugut, Rehema Winny, and Celine Ogari.</p><p>
<bold>Previous Presentations:</bold> Portions of this manuscript were presented at the 20<sup>th</sup> Conference on Retroviruses and Opportunistic Infections (CROI) in poster (L-104) and oral (L-115) presentations; March 3&#x02013;6, 2012, Atlanta GA, USA.</p><p>
<bold>Disclaimer:</bold> The views expressed here are the opinions of the authors and are not to be considered as official or reflecting the views of the Kenya Medical Research Institute, EmpiriStat, the Walter Reed Army Institute of Research, the US Army, the US Department of Defense, or the Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. This manuscript is published with the approval of the Director of the Kenya Medical Research Institute.</p></ack><ref-list><title>References</title><ref id="pone.0116299.ref001"><label>1</label><mixed-citation publication-type="book">
<collab>Department of Health and Human Services</collab>, <chapter-title>Panel on Antiretroviral Guidelines for Adults and Adolescents</chapter-title> (<year>2012</year>) <source>Guidelines for the use of antiretroviral agents in HIV-1-infected Adults and Adolescents</source>; <publisher-loc>Washington (DC)</publisher-loc>: <publisher-name>Department of Health and Human Services</publisher-name> Available: <ext-link ext-link-type="uri" xlink:href="http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf">http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</ext-link>. <comment>Accessed January 16, 2013</comment>.</mixed-citation></ref><ref id="pone.0116299.ref002"><label>2</label><mixed-citation publication-type="other">European AIDS Clinical Society (EACS). Guidelines v6.1 November 2012. Available: <ext-link ext-link-type="uri" xlink:href="http://www.eacsociety.org/Portals/0/files/pdf%20files/EacsGuidelines-v6.1-2edition.pdf">http://www.eacsociety.org/Portals/0/files/pdf%20files/EacsGuidelines-v6.1-2edition.pdf</ext-link>
</mixed-citation></ref><ref id="pone.0116299.ref003"><label>3</label><mixed-citation publication-type="other">World Health Organization (WHO) (2006) Antiretroviral Thearpy for HIV Infection in Adults and Adolscents in Resource Limited Settings: Towards Universal Access Recommendations for a Public Health Approach 2006 Revision. Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf?ua">http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf?ua</ext-link> = 1</mixed-citation></ref><ref id="pone.0116299.ref004"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Badri</surname><given-names>M</given-names></name>, <name><surname>Lawn</surname><given-names>SD</given-names></name>, <name><surname>Wood</surname><given-names>R</given-names></name> (<year>2008</year>) <article-title>Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting</article-title>. <source>BMC Infect Dis</source>
<volume>8</volume>:<fpage>89</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2334-8-89">10.1186/1471-2334-8-89</ext-link></comment>
<pub-id pub-id-type="pmid">18601727</pub-id></mixed-citation></ref><ref id="pone.0116299.ref005"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Eisenhut</surname><given-names>M</given-names></name> (<year>2008</year>) <article-title>Causes for low positive predictive values of CD4 counts for antiretroviral treatment failure</article-title>. <source>Int J Infect Dis</source>
<volume>12</volume>(<issue>5</issue>):<fpage>565</fpage>; <comment>author reply</comment>
<lpage>566</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ijid.2008.02.002.M">10.1016/j.ijid.2008.02.002. M</ext-link></comment>
<comment>Epub 2008 Apr 9</comment>
<pub-id pub-id-type="pmid">18403226</pub-id></mixed-citation></ref><ref id="pone.0116299.ref006"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Mee</surname><given-names>P</given-names></name>, <name><surname>Fielding</surname><given-names>KL</given-names></name>, <name><surname>Charalambous</surname><given-names>S</given-names></name>, <name><surname>Churchyard</surname><given-names>GJ</given-names></name>, <name><surname>Grant</surname><given-names>AD</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa</article-title>. <source>AIDS</source>
<volume>22</volume>(<issue>15</issue>):<fpage>1971</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAD.0b013e32830e4cd">10.1097/QAD.0b013e32830e4cd</ext-link></comment>
<pub-id pub-id-type="pmid">18784460</pub-id></mixed-citation></ref><ref id="pone.0116299.ref007"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Moore</surname><given-names>DM</given-names></name>, <name><surname>Awor</surname><given-names>A</given-names></name>, <name><surname>Downing</surname><given-names>R</given-names></name>, <name><surname>Kaplan</surname><given-names>J</given-names></name>, <name><surname>Montaner</surname><given-names>JS</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy</article-title>. <source>J Acquir Immune Defic Syndr</source>
<volume>49</volume>(<issue>5</issue>):<fpage>477</fpage>&#x02013;<lpage>84</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAI.0b013e318186eb18">10.1097/QAI.0b013e318186eb18</ext-link></comment>
<pub-id pub-id-type="pmid">18989232</pub-id></mixed-citation></ref><ref id="pone.0116299.ref008"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Reynolds</surname><given-names>SJ</given-names></name>, <name><surname>Nakigozi</surname><given-names>G</given-names></name>, <name><surname>Newell</surname><given-names>K</given-names></name>, <name><surname>Ndyanabo</surname><given-names>A</given-names></name>, <name><surname>Galiwongo</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda</article-title>. <source>AIDS</source>
<volume>23</volume>(<issue>6</issue>):<fpage>697</fpage>&#x02013;<lpage>700</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAD.0b013e3283262a78">10.1097/QAD.0b013e3283262a78</ext-link></comment>
<pub-id pub-id-type="pmid">19209067</pub-id></mixed-citation></ref><ref id="pone.0116299.ref009"><label>9</label><mixed-citation publication-type="other">World Health Organization (WHO) (2010) Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/arv/adult2010/en/">http://www.who.int/hiv/pub/arv/adult2010/en/</ext-link>.</mixed-citation></ref><ref id="pone.0116299.ref010"><label>10</label><mixed-citation publication-type="other">World Health Organization (WHO) (2013) Consolidated Guidelines on the Use of Antriretroviral Drug for Treatment and Preventing HIV Infection. Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/pub/guidelines/arv2013/download/en/">http://www.who.int/hiv/pub/guidelines/arv2013/download/en/</ext-link>
</mixed-citation></ref><ref id="pone.0116299.ref011"><label>11</label><mixed-citation publication-type="other">National AIDS and STI Control Program (NASCOP) (2011) Guidelines for Antiretroviral Therapy in Kenya 4th Edition. Available: <ext-link ext-link-type="uri" xlink:href="http://www.nascop.or.ke/library/ART%20guidelines/Final%20guidelines%20re%20print%2011-09-2012.pdf">http://www.nascop.or.ke/library/ART%20guidelines/Final%20guidelines%20re%20print%2011-09-2012.pdf</ext-link>
</mixed-citation></ref><ref id="pone.0116299.ref012"><label>12</label><mixed-citation publication-type="other">US Department of State. President&#x02019;s Budget Request Reflects Strong Commitment on Global AIDS. Available: <ext-link ext-link-type="uri" xlink:href="http://blogs.state.gov/index.php/site/entry/budget_global_aids">http://blogs.state.gov/index.php/site/entry/budget_global_aids</ext-link>. Accessed January 7, 2013.</mixed-citation></ref><ref id="pone.0116299.ref013"><label>13</label><mixed-citation publication-type="other">US Department of State. The President&#x02019;s Emergency Plan for AIDS Relief (PEPFAR) Blueprint: Creating an AIDS-free Generation. Available: <ext-link ext-link-type="uri" xlink:href="http://www.state.gov/r/pa/prs/ps/2012/11/201195.htm">http://www.state.gov/r/pa/prs/ps/2012/11/201195.htm</ext-link>. Accessed January 7, 2013.</mixed-citation></ref><ref id="pone.0116299.ref014"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Smith</surname><given-names>DM</given-names></name>, <name><surname>Schooley</surname><given-names>RT</given-names></name> (<year>2008</year>) <article-title>Running with scissors: using antiretroviral therapy without monitoring viral load</article-title>. <source>Clin Infect Dis</source>
<volume>46</volume>(<issue>10</issue>):<fpage>1598</fpage>&#x02013;<lpage>600</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/587110">10.1086/587110</ext-link></comment>
<pub-id pub-id-type="pmid">18419496</pub-id></mixed-citation></ref><ref id="pone.0116299.ref015"><label>15</label><mixed-citation publication-type="other">Clinic-based ART Diagnostic Evaluation (CLADE). The Walter Reed Army Institue of Research Institutional Review Board human use protocol # 1591 and Kenya Medical Research Institute Scientific Steering Committee #1717. Sponsored by the Office of the Global AIDS Coordinator (KE-07-0044).</mixed-citation></ref><ref id="pone.0116299.ref016"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Long</surname><given-names>L</given-names></name>, <name><surname>Fox</surname><given-names>M</given-names></name>, <name><surname>Sanne</surname><given-names>I</given-names></name>, <name><surname>Rosen</surname><given-names>S</given-names></name> (<year>2010</year>) <article-title>The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa</article-title>. <source>AIDS</source>
<volume>24</volume>(<issue>6</issue>):<fpage>915</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAD.0b013e3283360976">10.1097/QAD.0b013e3283360976</ext-link></comment>
<pub-id pub-id-type="pmid">20042849</pub-id></mixed-citation></ref><ref id="pone.0116299.ref017"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Long</surname><given-names>L</given-names></name>, <name><surname>Brennan</surname><given-names>A</given-names></name>, <name><surname>Fox</surname><given-names>MP</given-names></name>, <name><surname>Ndibongo</surname><given-names>B</given-names></name>, <name><surname>Jaffray</surname><given-names>I</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort</article-title>. <source>PLoS Med</source>
<volume>8</volume>(<issue>7</issue>):<fpage>e1001055</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1001055">10.1371/journal.pmed.1001055</ext-link></comment>
<comment>Epub 2011 Jul 19</comment>
<pub-id pub-id-type="pmid">21811402</pub-id></mixed-citation></ref><ref id="pone.0116299.ref018"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Larson</surname><given-names>BA</given-names></name>, <name><surname>Bii</surname><given-names>M</given-names></name>, <name><surname>Henly-Thomas</surname><given-names>S</given-names></name>, <name><surname>Sawe</surname><given-names>F</given-names></name>, <name><surname>Shaffer</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>ART treatment costs and retention in care in Kenya: a cohort study in three rural outpatient clinics</article-title>. <source>J Int AIDS Soc</source>
<volume>16</volume>:<fpage>18026</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.7448/IAS.16.1.18026">10.7448/IAS.16.1.18026</ext-link></comment>
<pub-id pub-id-type="pmid">23305696</pub-id></mixed-citation></ref><ref id="pone.0116299.ref019"><label>19</label><mixed-citation publication-type="other">Republic of Kenya. Kenya AIDS Indicator Survey (KAIS) 2007. Final Report 2009. Available at: <ext-link ext-link-type="uri" xlink:href="http://nascop.or.ke/library/3d/Official_KAIS_Report_20091.pdf">http://nascop.or.ke/library/3d/Official_KAIS_Report_20091.pdf</ext-link>
</mixed-citation></ref><ref id="pone.0116299.ref020"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Foglia</surname><given-names>G</given-names></name>, <name><surname>Sateren</surname><given-names>WB</given-names></name>, <name><surname>Renzullo</surname><given-names>PO</given-names></name>, <name><surname>Bautista</surname><given-names>CT</given-names></name>, <name><surname>Langat</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>High prevalence of HIV infection among rural tea plantation residents in Kericho, Kenya</article-title>. <source>Epidemiol Infect</source>. <year>2008</year>
<month>5</month>;<volume>136</volume>(<issue>5</issue>):<fpage>694</fpage>&#x02013;<lpage>702</lpage>. <comment>Epub 2007 Jun 29</comment>
<pub-id pub-id-type="pmid">17599780</pub-id></mixed-citation></ref><ref id="pone.0116299.ref021"><label>21</label><mixed-citation publication-type="other">Rono K, The Early Capture HIV Cohort (ECHO) Study (RV217b): Identifying Acute HIV Infection in Most at Risk Populations (MARPs) in Kericho, Kenya, in 16th International Conference on AIDS and STI&#x02019;s in Africa (ICASA) Addis Ababa, Ethiopia.</mixed-citation></ref><ref id="pone.0116299.ref022"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Shaffer</surname><given-names>DN</given-names></name>, <name><surname>Ngetich</surname><given-names>IK</given-names></name>, <name><surname>Sawe</surname><given-names>FK</given-names></name>, <name><surname>Kibaya</surname><given-names>RM</given-names></name>, <name><surname>Michael</surname><given-names>NL</given-names></name> (<year>2010</year>) <article-title>HIV-1 incidence rates and risk factors in agricultural workers and dependents in rural Kenya: 36-month follow-up of the Kericho HIV cohort study</article-title>. <source>J Acquir Immune Defic Syndr</source>
<volume>53</volume>(<issue>4</issue>):<fpage>514</fpage>&#x02013;<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAI.0b013e3181bcdae0">10.1097/QAI.0b013e3181bcdae0</ext-link></comment>
<pub-id pub-id-type="pmid">19855286</pub-id></mixed-citation></ref><ref id="pone.0116299.ref023"><label>23</label><mixed-citation publication-type="other">Kenya Open Data. Available: <ext-link ext-link-type="uri" xlink:href="https://opendata.go.ke/">https://opendata.go.ke/</ext-link>. Accessed January 29, 2013.</mixed-citation></ref><ref id="pone.0116299.ref024"><label>24</label><mixed-citation publication-type="other">The Kenya Medical Research Institute (KEMRI). Available: <ext-link ext-link-type="uri" xlink:href="http://www.kemri.org/">http://www.kemri.org/</ext-link>. Accessed January 7, 2013.</mixed-citation></ref><ref id="pone.0116299.ref025"><label>25</label><mixed-citation publication-type="other">U.S. Military HIV Research Program (MHRP). Available: <ext-link ext-link-type="uri" xlink:href="http://www.hivresearch.org/home.php">http://www.hivresearch.org/home.php</ext-link>. Accessed January 7, 2013.</mixed-citation></ref><ref id="pone.0116299.ref026"><label>26</label><mixed-citation publication-type="other">Available: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT01791556?">http://www.clinicaltrials.gov/ct2/show/NCT01791556?</ext-link>. Accessed May 28, 2013.</mixed-citation></ref><ref id="pone.0116299.ref027"><label>27</label><mixed-citation publication-type="other">Ministry of Health, Government of Kenya. Available: <ext-link ext-link-type="uri" xlink:href="http://www.statehousekenya.go.ke/government/health.htm">http://www.statehousekenya.go.ke/government/health.htm</ext-link>. Accesed January 7, 2013.</mixed-citation></ref><ref id="pone.0116299.ref028"><label>28</label><mixed-citation publication-type="other">Office of Human Research Protections (OHRP). Kenya Medical Research Institute. Available: <ext-link ext-link-type="uri" xlink:href="http://ohrp.cit.nih.gov/search/search.aspx">http://ohrp.cit.nih.gov/search/search.aspx</ext-link>. Accessed January 8, 2013.</mixed-citation></ref><ref id="pone.0116299.ref029"><label>29</label><mixed-citation publication-type="other">Office of Human Research Protections (OHRP). Tenwek Hospital. Available: <ext-link ext-link-type="uri" xlink:href="http://ohrp.cit.nih.gov/search/search.aspx">http://ohrp.cit.nih.gov/search/search.aspx</ext-link>. Accessed January 8, 2013.</mixed-citation></ref><ref id="pone.0116299.ref030"><label>30</label><mixed-citation publication-type="other">Office of Human Research Protections (OHRP). Walter Reed Army Institute of Research. Available: <ext-link ext-link-type="uri" xlink:href="http://ohrp.cit.nih.gov/search/search.aspx">http://ohrp.cit.nih.gov/search/search.aspx</ext-link>. Accessed January 8, 2013.</mixed-citation></ref><ref id="pone.0116299.ref031"><label>31</label><mixed-citation publication-type="other">The United States President&#x02019;s Emergency Plan for AIDS Relief. Available: <ext-link ext-link-type="uri" xlink:href="http://www.pepfar.gov/">http://www.pepfar.gov/</ext-link>. Accessed January 7, 2013.</mixed-citation></ref><ref id="pone.0116299.ref032"><label>32</label><mixed-citation publication-type="other">National AIDS and STD Control Programme (NASCOP), Ministry of Public Health and Sanitation (2008) National Guidelines for HIV Testing and Counseling in Kenya. Available: <ext-link ext-link-type="uri" xlink:href="http://www.nascop.or.ke/library/HTC/National%20Guidelines-HIV%20Testing%20and%20Counselling%20Kenya-2008.pdf">http://www.nascop.or.ke/library/HTC/National%20Guidelines-HIV%20Testing%20and%20Counselling%20Kenya-2008.pdf</ext-link>
</mixed-citation></ref><ref id="pone.0116299.ref033"><label>33</label><mixed-citation publication-type="other">National AIDS and STI Control Programme (NASCOP), Ministry of Public Health and Sanitation (2010) Guidelines for HIV Testing and Counselling and Kenya. Available: <ext-link ext-link-type="uri" xlink:href="http://www.nascop.or.ke/library/HTC/National%20Guidelines%20for%20HTC%20in%20Kenya%202010.pdf">http://www.nascop.or.ke/library/HTC/National%20Guidelines%20for%20HTC%20in%20Kenya%202010.pdf</ext-link>
</mixed-citation></ref><ref id="pone.0116299.ref034"><label>34</label><mixed-citation publication-type="other">Kenya Ministry of Public Health and Sanitation and Ministry of Medical Services (2010) Operational Manual for Implementing Provider-Initiated HIV Testing and Counseling in Clinical Settings. Available: <ext-link ext-link-type="uri" xlink:href="http://www.nascop.or.ke/library/HTC/">http://www.nascop.or.ke/library/HTC/</ext-link>.</mixed-citation></ref><ref id="pone.0116299.ref035"><label>35</label><mixed-citation publication-type="other">National AIDS and STI Control Programme (NASCOP) (2007) Kenya National Clinical Manual For ART Providers. Available: <ext-link ext-link-type="uri" xlink:href="http://www.nascop.or.ke/library/ART%20guidelines/Kenya%20clinical%20National%20Manual%20for%20ART%20providers.pdf">http://www.nascop.or.ke/library/ART%20guidelines/Kenya%20clinical%20National%20Manual%20for%20ART%20providers.pdf</ext-link>
</mixed-citation></ref><ref id="pone.0116299.ref036"><label>36</label><mixed-citation publication-type="other">National AIDS and STD Control Programme (NASCOP), Minstry of Health (2008) National Manual for the Management of HIV-Rleated Opportunistic Infections and Conditions. Available: <ext-link ext-link-type="uri" xlink:href="http://www.nascop.or.ke/library/ART%20guidelines/National%20Manual%20for%20the%20management%20of%20HIV%20related%20OIs.pdf">http://www.nascop.or.ke/library/ART%20guidelines/National%20Manual%20for%20the%20management%20of%20HIV%20related%20OIs.pdf</ext-link>
</mixed-citation></ref><ref id="pone.0116299.ref037"><label>37</label><mixed-citation publication-type="other">Division of Leprosy, Tuberculosis, and Lung Diseases (DLTLD), Ministry of Public Health and Sanitation (2009) Guidelines on management of Leprosy and Tuberculosis. Available: <ext-link ext-link-type="uri" xlink:href="http://www.nltp.co.ke/docs/Kenyan_TB_treatment_guidelines_2009.pdf">http://www.nltp.co.ke/docs/Kenyan_TB_treatment_guidelines_2009.pdf</ext-link>
</mixed-citation></ref><ref id="pone.0116299.ref038"><label>38</label><mixed-citation publication-type="other">Division of Leprosy, Tuberculosis, and Lung Diseases (DLTLD). Available: <ext-link ext-link-type="uri" xlink:href="http://www.nltp.co.ke/">http://www.nltp.co.ke/</ext-link>
</mixed-citation></ref><ref id="pone.0116299.ref039"><label>39</label><mixed-citation publication-type="other">Human Quality Assessment Services (HuQAS). Available: <ext-link ext-link-type="uri" xlink:href="http://www.huqas.org/">http://www.huqas.org/</ext-link>. Accessed January 9, 2013.</mixed-citation></ref><ref id="pone.0116299.ref040"><label>40</label><mixed-citation publication-type="other">College of American Pathologists (CAP). Available: <ext-link ext-link-type="uri" xlink:href="http://www.cap.org/apps/cap.portal">http://www.cap.org/apps/cap.portal</ext-link>. Accessed January 9, 2013.</mixed-citation></ref><ref id="pone.0116299.ref041"><label>41</label><mixed-citation publication-type="other">Collaborative Institutional Training Initiative (CITI). Available: <ext-link ext-link-type="uri" xlink:href="https://www.citiprogram.org/Default.asp">https://www.citiprogram.org/Default.asp</ext-link>. Accessed January 9, 2013.</mixed-citation></ref><ref id="pone.0116299.ref042"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Moore</surname><given-names>RD</given-names></name>, <name><surname>Keruly</surname><given-names>JC</given-names></name>, <name><surname>Gebo</surname><given-names>KA</given-names></name>, <name><surname>Lucas</surname><given-names>GM</given-names></name> (<year>2005</year>) <article-title>An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002</article-title>. <source>J Acquir Immune Defic Syndr</source>
<volume>39</volume>(<issue>2</issue>):<fpage>195</fpage>&#x02013;<lpage>8</lpage>.
<pub-id pub-id-type="pmid">15905736</pub-id></mixed-citation></ref><ref id="pone.0116299.ref043"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Shaffer</surname><given-names>DN</given-names></name>, <name><surname>Obiero</surname><given-names>ET</given-names></name>, <name><surname>Bett</surname><given-names>JB</given-names></name>, <name><surname>Kiptoo</surname><given-names>IN</given-names></name>, <name><surname>Maswai</surname><given-names>JK</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Successes and Challenges in an Integrated Tuberculosis/HIV Clinic in a Rural, Resource-Limited Setting: Experiences from Kericho, Kenya</article-title>. <source>AIDS Res Treat 2012</source>:<fpage>238012</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2012/238012">10.1155/2012/238012</ext-link></comment>
<comment>Epub 2012 Feb 16</comment>
<pub-id pub-id-type="pmid">22400104</pub-id></mixed-citation></ref><ref id="pone.0116299.ref044"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Padian</surname><given-names>NS</given-names></name>, <name><surname>Holmes</surname><given-names>CB</given-names></name>, <name><surname>McCoy</surname><given-names>SI</given-names></name>, <name><surname>Lyerla</surname><given-names>R</given-names></name>, <name><surname>Bouey</surname><given-names>PD</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Implementation science for the US President&#x02019;s Emergency Plan for AIDS Relief (PEPFAR)</article-title>. <source>J Acquir Immune Defic Syndr</source>
<volume>56</volume>(<issue>3</issue>):<fpage>199</fpage>&#x02013;<lpage>203</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/QAI.0b013e31820bb448">10.1097/QAI.0b013e31820bb448</ext-link></comment>
<pub-id pub-id-type="pmid">21239991</pub-id></mixed-citation></ref><ref id="pone.0116299.ref045"><label>45</label><mixed-citation publication-type="journal">
<collab>Antiretroviral Therapy Cohort Collaboration</collab> (<year>2008</year>) <article-title>Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies</article-title>. <source>Lancet</source>
<volume>372</volume>(<issue>9635</issue>):<fpage>293</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(08)61113-7">10.1016/S0140-6736(08)61113-7</ext-link></comment>
<pub-id pub-id-type="pmid">18657708</pub-id></mixed-citation></ref><ref id="pone.0116299.ref046"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Egger</surname><given-names>M</given-names></name>, <name><surname>May</surname><given-names>M</given-names></name>, <name><surname>Ch&#x000ea;ne</surname><given-names>G</given-names></name>, <name><surname>Phillips</surname><given-names>AN</given-names></name>, <collab>ART Cohort Collaboration</collab>, <etal>et al</etal> (<year>2002</year>) <article-title>Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies</article-title>. <source>Lancet</source>
<volume>360</volume>(<issue>9327</issue>):<fpage>119</fpage>&#x02013;<lpage>29</lpage>. Erratum in: Lancet 2002 Oct 12;360(9340):1178. PMID: 12126821
<pub-id pub-id-type="pmid">12126821</pub-id></mixed-citation></ref><ref id="pone.0116299.ref047"><label>47</label><mixed-citation publication-type="journal">
<collab>DART Trial Team</collab>, <name><surname>Mugyenyi</surname><given-names>P</given-names></name>, <name><surname>Walker</surname><given-names>AS</given-names></name>, <name><surname>Hakim</surname><given-names>J</given-names></name>, <name><surname>Munderi</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial</article-title>. <source>Lancet</source>
<volume>375</volume>(<issue>9709</issue>):<fpage>123</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(09)62067-5">10.1016/S0140-6736(09)62067-5</ext-link></comment>
<comment>Epub 2009 Dec 8</comment>
<pub-id pub-id-type="pmid">20004464</pub-id></mixed-citation></ref><ref id="pone.0116299.ref048"><label>48</label><mixed-citation publication-type="journal">
<collab>ARROW Trial team</collab>, <name><surname>Kekitiinwa</surname><given-names>A</given-names></name>, <name><surname>Cook</surname><given-names>A</given-names></name>, <name><surname>Nathoo</surname><given-names>K</given-names></name>, <name><surname>Mugyenyi</surname><given-names>P</given-names></name> (<year>2013</year>) <article-title>Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial</article-title>. <source>Lancet</source>
<volume>381</volume>(<issue>9875</issue>):<fpage>1391</fpage>&#x02013;<lpage>403</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(12)62198-9">10.1016/S0140-6736(12)62198-9</ext-link></comment>
<comment>Epub 2013 Mar 7</comment>
<pub-id pub-id-type="pmid">23473847</pub-id></mixed-citation></ref><ref id="pone.0116299.ref049"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Mermin</surname><given-names>J</given-names></name>, <name><surname>Ekwaru</surname><given-names>JP</given-names></name>, <name><surname>Were</surname><given-names>W</given-names></name>, <name><surname>Degerman</surname><given-names>R</given-names></name>, <name><surname>Bunnell</surname><given-names>R</given-names></name>, <name><surname>Kaharuza</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial</article-title>. <source>BMJ 9</source>;<volume>343</volume>:<fpage>d6792</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.d6792">10.1136/bmj.d6792</ext-link></comment>
<pub-id pub-id-type="pmid">22074711</pub-id></mixed-citation></ref><ref id="pone.0116299.ref050"><label>50</label><mixed-citation publication-type="journal">
<name><surname>Koethe</surname><given-names>JR</given-names></name>, <name><surname>Westfall</surname><given-names>AO</given-names></name>, <name><surname>Luhanga</surname><given-names>DK</given-names></name>, <name><surname>Clark</surname><given-names>GM</given-names></name>, <name><surname>Goldman</surname><given-names>JD</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>A cluster randomized trial of routine HIV-1 viral load monitoring in Zambia: study design, implementation, and baseline cohort characteristics</article-title>. <source>PLoS One 12</source>;<volume>5</volume>(<issue>3</issue>):<fpage>e9680</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0009680">10.1371/journal.pone.0009680</ext-link></comment>
<comment>Erratum in PLoS One. 2010; 5(3)</comment>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/annotation/dbc3ee9b-dab4-494b-87d1-7c32b8d684b5">10.1371/annotation/dbc3ee9b-dab4-494b-87d1-7c32b8d684b5</ext-link></comment>.</mixed-citation></ref></ref-list></back></article>